SCHEMBL643845

SCHEMBL643845

COc1ccccc1C1CC(=O)CC(=O)C1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 2/20 0.57
TP53 P04637 1/20 0.56
RECQL P46063 1/20 0.56
HTR2C P28335 2/20 0.53
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
USP2 O75604 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
PKM P14618 1/20 0.46
ADRA1A P35348 2/20 0.46
DRD2 P14416 1/20 0.45
CYP19A1 P11511 2/20 0.45
ADRA1D P25100 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30368251 1.00 MAP1LC3B (0.57) MAP1LC3BTP53RECQLHTR2CMAPT
SCHEMBL11350470 0.91 MAP1LC3B (0.50) MAP1LC3BTP53RECQLHTR2CMAPT
SCHEMBL30384404 0.86 MAP1LC3B (0.54) MAP1LC3BHTR2CMAPTMEN1KMT2A
SCHEMBL14950769 0.85 TSHR (0.49) MAP1LC3BTP53RECQLMAPTGAA
SCHEMBL29008634 0.85 MAP1LC3B (0.45) MAP1LC3BTP53RECQLHTR2CMAPT
SCHEMBL12635245 0.83 ADRA1A (0.55) MAP1LC3BHTR2CMEN1KMT2AUSP2
SCHEMBL30129583 0.83 ADRA1A (0.55) MAP1LC3BHTR2CMEN1KMT2AUSP2
SCHEMBL12635239 0.83 ADRA1A (0.55) MAP1LC3BHTR2CMEN1KMT2AUSP2
SCHEMBL12667873 0.83 ADRA1A (0.55) MAP1LC3BHTR2CMEN1KMT2AUSP2
SCHEMBL824116 0.81 HTR2C (0.53) MAP1LC3BHTR2CMEN1KMT2AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113563509-B Composition for preparing fracturing thickening agent, fracturing thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2021-12-07 CN claimed
CN-113563509-A Composition for preparing fracturing thickening agent, fracturing thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2021-10-29 CN claimed
EP-4727923-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA University of Georgia Research Foundation, Inc. (US) 2026-04-22 EP disclosed
US-20260102387-A1 IMMUNOSUPPRESSIVE COMPOUNDS UNIV BASEL (CH) 2026-04-16 US disclosed
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIV GEORGIA (US) 2026-04-09 US disclosed
US-12209172-B2 Curable compositions and methods of using the same 3M INNOVATIVE PROPERTIES COMPANY (US) 2025-01-28 US disclosed
WO-2024258904-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2024-12-19 WO disclosed
WO-2024069007-A2 IMMUNOSUPPRESSIVE COMPOUNDS UNIVERSITÄT BASEL (CH) 2024-04-04 WO disclosed
US-20230133261-A1 CURABLE COMPOSITIONS AND METHODS OF USING THE SAME 3M INNOVATIVE PROPERTIES COMPANY 2023-05-04 US disclosed
CN-115380053-A Curable compositions and methods of using curable compositions 3M创新有限公司 2022-11-22 CN disclosed
CN-113563509-B Composition for preparing fracturing thickening agent, fracturing thickening agent and preparation method thereof 山东诺尔生物科技有限公司 2021-12-07 CN disclosed
EP-2249818-A1 HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE Stanford University (US) 2010-11-17 EP disclosed
EP-2144889-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC S.r.l. (IT) 2010-01-20 EP disclosed
WO-2009102864-A1 HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE STANFORD UNIVERSITY (US) 2009-08-20 WO disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 WO disclosed
WO-2008142720-A2 QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS DAC SRL (IT) 2008-11-27 WO disclosed
EP-1229019-A1 PROCESS FOR THE PRODUCTION OF OPTICALLY ACTIVE CYCLIC ENAMINONE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2002-08-07 EP disclosed
US-6350749-B1 SODIUM CHANNEL MODULATORS, ANTIARRHYTHMIA AND HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS, ANGINA PECTORIS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-02-26 US disclosed
EP-1057812-A1 AMINOGUANIDINE HYDRAZONE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND DRUGS THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-12-06 EP disclosed
US-4315006-A Benzoxocin derivatives having anxiolytic and anti-convulsant activities GLAXO GROUP LIMITED (GB) 1982-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209172-B2 Curable compositions and methods of using the same MAT2B, MAT1A, MTR MAP1LC3B 204/4885TP53 2295/4885RECQL 1087/4885
US-20260098012-A1 TETRAHYDROACRIDINONE ANALOGUES FOR TREATMENT AND PREVENTION OF MALARIA CD47, SLC11A2, G6PD MAP1LC3B 288/4885TP53 4266/4885RECQL 2106/4885
US-20230133261-A1 CURABLE COMPOSITIONS AND METHODS OF USING THE SAME MAT2B, MAT1A, MTR MAP1LC3B 204/4885TP53 2295/4885RECQL 1087/4885
US-20260102387-A1 IMMUNOSUPPRESSIVE COMPOUNDS CHP1, BRD3, IRF3 MAP1LC3B 2145/4885TP53 1138/4885RECQL 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.